Lilly has announced that the company has launched the study of the world’s first potential Covid-19 antibody treatment in Humans. The company has further said that the study names as the LY-CoV555, and it is done after the collaboration with the AbCellera and Lilly to find the potential treatment of Covid-19 pandemic. The first patient in the study was selected from the major medical center in the U.S, including Cedars-Sinai in Los Angeles and NYU Grossman School of Medicine.
Director of the Division of Infectious Diseases and Immunology and director of the Vaccine Center at NYU Langone Health, Mark J. Mulligan said, “We are committed to working with our industry partners to generate scientific evidence to meet the urgent need for treatments that reduce the severity of COVID-19 disease.”
“Antibody treatments like the one being studied here hold promise to be effective medical countermeasures against this deadly infection,” Mark Mulligan further added in his statement.
Chief scientific officer and president of Lilly Research Laboratories, Daniel Skovronsky, M.D Ph.D. said, “We are grateful to collaborate with colleagues at AbCellera, NIAID, and the many academic institutions who have helped us reach this milestone in humanity’s fight against COVID-19 — a disease first characterized only six months ago. We are privileged to help usher in this new era of drug development with the first potential new medicine specifically designed to attack the virus.”
“Antibody therapies such as LY-CoV555 may have potential for both prevention and treatment of COVID-19 and may be particularly important for groups hardest hit by the disease such as the elderly and those with compromised immune systems,” Daniel Skovronsky further added.
“Later this month, we will review the results of this first human study and intend to initiate broader efficacy trials. At the same time as we are investigating safety and efficacy, we also are starting large-scale manufacturing of this potential therapy,” Lovronsky concluded.